Olatec gets $40M to put an­ti-in­flam­ma­to­ry in late-stage tri­al; En­liv­en goes pub­lic, rais­es $165M

A US and Dutch biotech closed its $40 mil­lion Se­ries A to bankroll more stud­ies of its oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.